Clorox (NYSE:CLX) PT Set at $119.00 by Barclays

Clorox (NYSE:CLX - Get Free Report) received a $119.00 price target from equities researchers at Barclays in a report issued on Tuesday, MarketBeat reports. The firm presently has an "underweight" rating on the stock. Barclays's target price indicates a potential downside of 6.21% from the company's previous close.

A number of other research firms have also weighed in on CLX. Jefferies Financial Group reduced their target price on shares of Clorox from $167.00 to $145.00 and set a "buy" rating on the stock in a report on Thursday, June 26th. UBS Group reduced their price objective on shares of Clorox from $176.00 to $154.00 and set a "neutral" rating on the stock in a research note on Thursday, April 17th. Morgan Stanley lowered their target price on Clorox from $165.00 to $150.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. JPMorgan Chase & Co. cut their target price on Clorox from $151.00 to $144.00 and set a "neutral" rating on the stock in a report on Tuesday, May 6th. Finally, Wells Fargo & Company decreased their price target on Clorox from $142.00 to $135.00 and set an "equal weight" rating for the company in a research note on Wednesday, July 9th. Three analysts have rated the stock with a sell rating, ten have given a hold rating and one has given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $146.83.

Clorox Price Performance

Shares of NYSE CLX traded up $2.71 during mid-day trading on Tuesday, hitting $126.88. 1,567,620 shares of the stock traded hands, compared to its average volume of 1,420,579. The company has a market cap of $15.64 billion, a PE ratio of 22.78, a price-to-earnings-growth ratio of 3.06 and a beta of 0.51. Clorox has a twelve month low of $117.35 and a twelve month high of $171.37. The company has a debt-to-equity ratio of 13.07, a current ratio of 0.74 and a quick ratio of 0.44. The firm has a 50 day simple moving average of $127.65 and a two-hundred day simple moving average of $141.81.

Clorox (NYSE:CLX - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported $1.45 EPS for the quarter, missing analysts' consensus estimates of $1.57 by ($0.12). The firm had revenue of $1.67 billion for the quarter, compared to analyst estimates of $1.74 billion. Clorox had a net margin of 9.89% and a return on equity of 324.23%. The business's revenue for the quarter was down 8.0% compared to the same quarter last year. During the same period in the previous year, the business posted $1.71 earnings per share. As a group, equities research analysts forecast that Clorox will post 7.15 EPS for the current fiscal year.

Insider Activity at Clorox

In other Clorox news, Director Pierre R. Breber bought 4,000 shares of the stock in a transaction on Wednesday, May 7th. The stock was acquired at an average cost of $136.57 per share, for a total transaction of $546,280.00. Following the completion of the acquisition, the director owned 4,000 shares in the company, valued at $546,280. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. 0.57% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Redwood Park Advisors LLC bought a new stake in shares of Clorox during the fourth quarter valued at approximately $26,000. American National Bank & Trust lifted its stake in shares of Clorox by 69.5% in the second quarter. American National Bank & Trust now owns 217 shares of the company's stock valued at $26,000 after buying an additional 89 shares in the last quarter. Millstone Evans Group LLC acquired a new position in shares of Clorox during the fourth quarter valued at about $31,000. Wood Tarver Financial Group LLC acquired a new position in shares of Clorox during the fourth quarter valued at about $31,000. Finally, GKV Capital Management Co. Inc. bought a new stake in shares of Clorox during the fourth quarter worth about $32,000. Institutional investors and hedge funds own 78.53% of the company's stock.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.